Cellular and Molecular Life Sciences

, Volume 67, Issue 22, pp 3915–3925

Identification of cancer stem cell-like cells from human epithelial ovarian carcinoma cell line

Research Article

Abstract

Cancer stem cells (CSCs) play an important role in the development, invasion, and drug resistance of carcinoma, but the exact phenotype and characteristics of ovarian CSCs are still disputable. In this study, we identified cancer stem cell-like cells (CSC-LCs) and investigated their characteristics from the ovarian adenocarcinoma cell line 3AO. Our results showed that CSC-LCs were enriched in sphere-forming test and highly expressed CD44+CD24. The spheres and CD24 cells possessed strong tumorigenic ability by transplantation into nonobese diabetic/severe combined immunodeficient mice. CD44+CD24 cells expressed stem cell markers and differentiated to CD44+CD24+ cells by immunofluorescence assay and fluorescence-activated cell-sorting analysis. In vitro experiments verified that CD44+CD24 cells were markedly resistant to carboplatin and paclitaxol. In conclusion, our study identifies the CD44+CD24 phenotype, self-renewal, high tumorigenicity, differentiation potential, and drug resistance of ovarian CSC-LCs. Our findings may provide the evidence needed to explore a new strategy in the treatment of ovarian cancer.

Keywords

Cancer stem cells Ovarian carcinoma CD44 CD24 

References

  1. 1.
    Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, Visvader J, Weissman IL, Wahl GM (2006) Cancer stem cells—perspectives on current status and future directions: AACR workshop on cancer stem cells. Cancer Res 66:9339–9344CrossRefPubMedGoogle Scholar
  2. 2.
    Bonnet D, Dick JE (1997) Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3:730–737CrossRefPubMedGoogle Scholar
  3. 3.
    Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100:3983–3988CrossRefPubMedGoogle Scholar
  4. 4.
    Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PB (2004) Identification of human brain tumour initiating cells. Nature 432:396–401CrossRefPubMedGoogle Scholar
  5. 5.
    Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ (2005) Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 65:10946–10951CrossRefPubMedGoogle Scholar
  6. 6.
    Dalerba P, Cho RW, Clarke MF (2007) Cancer stem cells: models and concepts. Annu Rev Med 58:267–284CrossRefPubMedGoogle Scholar
  7. 7.
    Olempska M, Eisenach PA, Ammerpohl O, Ungefroren H, Fandrich F, Kalthoff H (2007) Detection of tumor stem cell markers in pancreatic carcinoma cell lines. Hepatobiliary Pancreat Dis Int 6:92–97PubMedGoogle Scholar
  8. 8.
    Zhang S, Balch C, Chan MW, Lai HC, Matei D, Schilder JM, Yan PS, Huang TH, Nephew KP (2008) Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res 68:4311–4320CrossRefPubMedGoogle Scholar
  9. 9.
    Fong MY, Kakar SS (2010) The role of cancer stem cells and the side population in epithelial ovarian cancer. Histol Histopathol 25:113–120PubMedGoogle Scholar
  10. 10.
    Jordan CT, Guzman ML, Noble M (2006) Cancer stem cells. N Engl J Med 355:1253–1261CrossRefPubMedGoogle Scholar
  11. 11.
    Reya T, Morrison SJ, Clarke MF, Weissman IL (2001) Stem cells, cancer, and cancer stem cells. Nature 414:105–111CrossRefPubMedGoogle Scholar
  12. 12.
    Mimeault M, Hauke R, Mehta PP, Batra SK (2007) Recent advances in cancer stem/progenitor cell research: therapeutic implications for overcoming resistance to the most aggressive cancers. J Cell Mol Med 11:981–1011CrossRefPubMedGoogle Scholar
  13. 13.
    Croker AK, Allan AL (2008) Cancer stem cells: implications for the progression and treatment of metastatic disease. J Cell Mol Med 12:374–390CrossRefPubMedGoogle Scholar
  14. 14.
    Nossov V, Amneus M, Su F, Lang J, Janco JM, Reddy ST, Farias-Eisner R (2008) The early detection of ovarian cancer: from traditional methods to proteomics. Can we really do better than serum CA-125? Am J Obstet Gynecol 199:215–223CrossRefPubMedGoogle Scholar
  15. 15.
    Bapat SA, Mali AM, Koppikar CB, Kurrey NK (2005) Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer. Cancer Res 65:3025–3029PubMedGoogle Scholar
  16. 16.
    Baba T, Convery PA, Matsumura N, Whitaker RS, Kondoh E, Perry T, Huang Z, Bentley RC, Mori S, Fujii S, Marks JR, Berchuck A, Murphy SK (2009) Epigenetic regulation of CD133 and tumorigenicity of CD133 + ovarian cancer cells. Oncogene 28:209–218CrossRefPubMedGoogle Scholar
  17. 17.
    Tang DG, Patrawala L, Calhoun T, Bhatia B, Choy G, Schneider-Broussard R, Jeter C (2007) Prostate cancer stem/progenitor cells: identification, characterization, and implications. Mol Carcinog 46:1–14CrossRefPubMedGoogle Scholar
  18. 18.
    Chambers I, Smith A (2004) Self-renewal of teratocarcinoma and embryonic stem cells. Oncogene 23:7150–7160CrossRefPubMedGoogle Scholar
  19. 19.
    Locke M, Heywood M, Fawell S, Mackenzie IC (2005) Retention of intrinsic stem cell hierarchies in carcinoma-derived cell lines. Cancer Res 65:8944–8950CrossRefPubMedGoogle Scholar
  20. 20.
    Fang D, Nguyen TK, Leishear K, Finko R, Kulp AN, Hotz S, Van Belle PA, Xu X, Elder DE, Herlyn M (2005) A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res 65:9328–9337CrossRefPubMedGoogle Scholar
  21. 21.
    Bunting KD (2002) ABC transporters as phenotypic markers and functional regulators of stem cells. Stem Cells 20:11–20CrossRefPubMedGoogle Scholar
  22. 22.
    Mizrak D, Brittan M, Alison MR (2008) CD133: molecule of the moment. J Pathol 214:3–9CrossRefPubMedGoogle Scholar
  23. 23.
    Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, Dirks PB (2003) Identification of a cancer stem cell in human brain tumors. Cancer Res 63:5821–5828PubMedGoogle Scholar
  24. 24.
    Suetsugu A, Nagaki M, Aoki H, Motohashi T, Kunisada T, Moriwaki H (2006) Characterization of CD133 + hepatocellular carcinoma cells as cancer stem/progenitor cells. Biochem Biophys Res Commun 351:820–824CrossRefPubMedGoogle Scholar
  25. 25.
    Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, Wicha M, Clarke MF, Simeone DM (2007) Identification of pancreatic cancer stem cells. Cancer Res 67:1030–1037CrossRefPubMedGoogle Scholar
  26. 26.
    Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, De Maria R (2007) Identification and expansion of human colon-cancer-initiating cells. Nature 445:111–115CrossRefPubMedGoogle Scholar
  27. 27.
    Eramo A, Lotti F, Sette G, Pilozzi E, Biffoni M, Di Virgilio A, Conticello C, Ruco L, Peschle C, De Maria R (2008) Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ 15:504–514CrossRefPubMedGoogle Scholar
  28. 28.
    Ferrandina G, Bonanno G, Pierelli L, Perillo A, Procoli A, Mariotti A, Corallo M, Martinelli E, Rutella S, Paglia A, Zannoni G, Mancuso S, Scambia G (2008) Expression of CD133–1 and CD133–2 in ovarian cancer. Int J Gynecol Cancer 18:506–514CrossRefPubMedGoogle Scholar
  29. 29.
    Inoue M, Kyo S, Fujita M, Enomoto T, Kondoh G (1994) Coexpression of the c-kit receptor and the stem cell factor in gynecological tumors. Cancer Res 54:3049–3053PubMedGoogle Scholar
  30. 30.
    Tonary AM, Macdonald EA, Faught W, Senterman MK, Vanderhyden BC (2000) Lack of expression of c-KIT in ovarian cancers is associated with poor prognosis. Int J Cancer 89:242–250CrossRefPubMedGoogle Scholar
  31. 31.
    Shaw TJ, Keszthelyi EJ, Tonary AM, Cada M, Vanderhyden BC (2002) Cyclic AMP in ovarian cancer cells both inhibits proliferation and increases c-KIT expression. Exp Cell Res 273:95–106CrossRefPubMedGoogle Scholar
  32. 32.
    Tai MH, Chang CC, Kiupel M, Webster JD, Olson LK, Trosko JE (2005) Oct4 expression in adult human stem cells: evidence in support of the stem cell theory of carcinogenesis. Carcinogenesis 26:495–502CrossRefPubMedGoogle Scholar
  33. 33.
    Kondo T (2006) Brain cancer stem-like cells. Eur J Cancer 42:1237–1242CrossRefPubMedGoogle Scholar
  34. 34.
    Ponti D, Zaffaroni N, Capelli C, Daidone MG (2006) Breast cancer stem cells: an overview. Eur J Cancer 42:1219–1224CrossRefPubMedGoogle Scholar
  35. 35.
    Soltysova A, Altanerova V, Altaner C (2005) Cancer stem cells. Neoplasma 52:435–440PubMedGoogle Scholar
  36. 36.
    Min C, Eddy SF, Sherr DH, Sonenshein GE (2008) NF-kappaB and epithelial to mesenchymal transition of cancer. J Cell Biochem 104:733–744CrossRefPubMedGoogle Scholar
  37. 37.
    Kong D, Wang Z, Sarkar SH, Li Y, Banerjee S, Saliganan A, Kim HR, Cher ML, Sarkar FH (2008) Platelet-derived growth factor-D overexpression contributes to epithelial-mesenchymal transition of PC3 prostate cancer cells. Stem Cells 26:1425–1435CrossRefPubMedGoogle Scholar
  38. 38.
    Larue L, Bellacosa A (2005) Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3’ kinase/AKT pathways. Oncogene 24:7443–7454CrossRefPubMedGoogle Scholar
  39. 39.
    Thiery JP (2002) Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2:442–454CrossRefPubMedGoogle Scholar
  40. 40.
    Kang Y, Massague J (2004) Epithelial-mesenchymal transitions: twist in development and metastasis. Cell 118:277–279CrossRefPubMedGoogle Scholar
  41. 41.
    Yoshida J, Horiuchi A, Kikuchi N, Hayashi A, Osada R, Ohira S, Shiozawa T, Konishi I (2009) Changes in the expression of E-cadherin repressors, Snail, Slug, SIP1, and Twist, in the development and progression of ovarian carcinoma: the important role of Snail in ovarian tumorigenesis and progression. Med Mol Morphol 42:82–91CrossRefPubMedGoogle Scholar

Copyright information

© Springer Basel AG 2010

Authors and Affiliations

  1. 1.Department of Gynecologic Oncology, Women’s Hospital, School of Medicine, Women’s Reproductive Health Laboratory of Zhejiang ProvinceZhejiang UniversityHangzhouChina
  2. 2.Shanghai Cancer InstituteShanghai Jiao Tong UniversityShanghaiChina
  3. 3.Cancer Biology Research Center, Tongji Hospital, Tongji Medical CollegeHuazhong University of Science and TechnologyWuhanChina

Personalised recommendations